<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Reactions to the hemodialysis membrane</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Reactions to the hemodialysis membrane</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Reactions to the hemodialysis membrane</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alessandro Bellucci, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steve J Schwab, MD, FACP, FASN</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Dialyzer reactions refer to all of the abnormal sequelae resulting from the interaction between blood constituents and the hemodialysis membrane. There are two types of reactions: type A and type B [<a href="#rid1">1</a>]. In the past, these reactions were grouped under the term "first-use syndrome" because they primarily occurred with new dialyzers. Before discussing the characteristics of these disorders, it is helpful to review the different types of dialyzers since they can affect the frequency and type of reaction seen. The longer-term clinical consequences of exposure to dialysis membranes are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1873.html" rel="external">"Clinical consequences of hemodialysis membrane biocompatibility"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TYPES OF HEMODIALYSIS MEMBRANES</span><span class="headingEndMark"> — </span>There are four types of membranes currently used to manufacture dialyzers [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cellulose, also called cuprophan (or cuprophane), is a polysaccharide-based membrane obtained from pressed cotton. It is composed of chains of glucosan rings with abundant free hydroxyl groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Substituted cellulose membranes are obtained by chemical bonding of a material to the free hydroxyl groups at the surface of the cellulose polymer. The most common type is cellulose acetate, in which acetate replaces 80 percent of the hydroxyl groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cellulosynthetic membranes are modified by the addition of a synthetic material (such as diethylaminoethyl in the production of hemophane) to liquefied cellulose during its formation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Synthetic noncellulose membranes, which have a higher permeability and are more biocompatible (and more expensive) than the cellulose membranes. There are a variety of synthetic membranes available, including polyacrylonitrile (PAN), acrylonitrile-sodium methallyl sulfonate (AN-69), polysulfone, polycarbonate, polyamide, and polymethylmethacrylate (PMMA) membranes.</p><p></p><p class="headingAnchor" id="H3"><span class="h1">TYPE A REACTIONS</span><span class="headingEndMark"> — </span>Type A reactions are estimated to occur in approximately 4 of every 100,000 dialysis treatments. They usually begin in the <strong>first few minutes</strong> of dialysis, immediately after the return of blood from the dialysis circuit to the patient; in occasional cases, however, the onset is delayed for up to 30 minutes into the treatment [<a href="#rid1">1</a>].</p><p>The associated symptoms range from mild to severe [<a href="#rid1">1</a>]. Mild cases may be associated with a variety of symptoms such as itching, burning sensation at the access site, urticaria, flushing, cough, sneezing, wheezing, abdominal cramps, diarrhea, headache, back and chest pain, nausea, vomiting, fever, and chills. More severe reactions lead to dyspnea, a sense of impending doom, and hypotension, potentially resulting in cardiac arrest and death. Patients with an allergic diathesis and eosinophilia appear to be predisposed to this type of reaction.</p><p class="headingAnchor" id="H4"><span class="h2">Etiology</span><span class="headingEndMark"> — </span>Type A reactions are probably largely caused by leachable substances from the dialyzer or by contamination with bacterial peptides. A classic cause of this type of reaction is <strong>ethylene oxide</strong>, which is used to sterilize hollow fiber dialyzers. Reactions to ethylene oxide, which are now uncommon, occur exclusively during the first use, usually when there has been inadequate rinsing of the dialyzer prior to use. Immunoglobulin E (IgE) antibodies directed against ethylene oxide are present in some cases, particularly those with more severe reactions [<a href="#rid3">3</a>].</p><p>One study, for example, found that 16 of 106 unselected patients developed mild allergic symptoms after hemodialysis; 10 of these patients also developed eosinophilia [<a href="#rid4">4</a>]. Two observations suggested an important role for ethylene oxide in this response: Allergy to ethylene oxide could be demonstrated in seven of the cases, and the symptoms and eosinophilia were ameliorated in three patients by ethylene oxide-free hemodialysis. Patients with eosinophilia also have a greater degree of complement activation and interleukin-2 production after exposure to a cuprophane membrane [<a href="#rid4">4,5</a>]. These exaggerated responses may be related in part to an underlying allergic diathesis.</p><p>A high incidence of anaphylactoid reactions is also seen when angiotensin-converting enzyme (ACE) inhibitors are used in patients treated with high-flux hemodialysis using acrylonitrile-sodium methallyl sulfonate (AN-69) dialyzers [<a href="#rid6">6-8</a>]. One report, for example, surveyed dialysis centers reporting anaphylactic reactions [<a href="#rid6">6</a>]. An anaphylactic reaction developed in 41 of 72 patients (57 percent) treated with an ACE inhibitor and dialyzed with an AN-69 membrane. In contrast, an anaphylactic reaction developed in none of the 71 patients taking an ACE inhibitor but dialyzed with other membranes and in only 2 of 519 patients (0.4 percent) dialyzed with AN-69 membrane but not treated with an ACE inhibitor.</p><p>These membranes appear to act by increasing the rate of kinin generation [<a href="#rid9">9,10</a>]. The following mechanism has been proposed to explain the susceptibility associated with AN-69 membranes. Contact of blood with a dialysis membrane leads to binding of Hageman factor (factor XII) and circulating complexes of high-molecular-weight kininogen with prekallikrein. Activation of prekallikrein by Hageman factor results in the formation of kallikrein, which cleaves bradykinin from kininogen. Activation of this process is facilitated by a negatively charged surface, which induces conformational changes in Hageman factor. Polyacrylonitrile (PAN) membranes are highly negatively charged, while cellulosic membranes have a neutral charge [<a href="#rid9">9</a>].</p><p>The ensuing enhancement of bradykinin production is generally well tolerated, unless the patient is taking an ACE inhibitor. ACE is also a kininase. Thus, blocking converting enzyme prevents inactivation of bradykinin, thereby raising bradykinin levels as much as <strong>20- to 30-fold</strong> and increasing the likelihood of an anaphylactoid reaction [<a href="#rid10">10</a>].</p><p>The association of anaphylactoid reaction with hypochlorite (bleach)-reprocessed, but not formalin-reprocessed, AN-69 dialyzers is also consistent with the importance of surface activation of Hageman factor [<a href="#rid11">11</a>]. Hypochlorite, a strong, oxidizing agent, removes the protein coat from the used dialysis membranes and is therefore likely to activate factor XII. On the other hand, formaldehyde fixes the protein layer on the surface, thereby reducing the chance for further activation of the Hageman factor.</p><p>The use of AN-69 membranes for continuous kidney replacement therapy (CKRT) has moved the occurrence of this type of reaction from the dialysis unit to the critical care setting. Priming of the CKRT circuit with packed red blood cells has been associated with severe hypotension, which was only responsive to the removal of the CKRT circuit in two pediatric patients [<a href="#rid12">12</a>]. Neither of these children was on an ACE inhibitor. The reaction was prevented by buffering the blood to a physiologic pH prior to priming the CKRT circuit or by infusing the packed red blood cells after the dialyzer (postdilution). The authors postulated that an acid pH enhanced the generation of bradykinins at the time of the blood-membrane interaction. This raises the possibility that alkali administration may prevent anaphylactoid reactions in patients on ACE inhibitors dialyzed with the AN-69 membrane [<a href="#rid13">13</a>].</p><p>Surface treatment of AN-69 membranes with a biocompatible polymer (AN-69 ST) results in partial neutralization of the surface electronegativity, dramatically reducing bradykinin release [<a href="#rid14">14</a>]. Patients with a history of anaphylactoid reaction to AN-69 membranes while taking ACE inhibitors have been successfully dialyzed with AN-69 ST membranes while still taking the ACE inhibitors [<a href="#rid15">15</a>]. This experience further confirms the role of the electronegative charge and the generation of bradykinins as the causative factor for these reactions.</p><p>Anaphylactoid reactions have also been associated with reused polysulfone and cellulose acetate dialyzers [<a href="#rid16">16</a>]. However, the role of ACE inhibitors in this setting is less certain.</p><p>Anaphylactoid reactions have also been reported among patients receiving angiotensin II receptor blockers (ARBs) during hemodialysis with AN69 membranes [<a href="#rid17">17,18</a>]. However, since ARBs do not affect bradykinin levels, the exact underlying mechanism is unclear.</p><p>Type A reactions can also be seen in a number of other settings [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>High-flux dialyzers used in conjunction with bicarbonate dialysate are susceptible to contamination with bacterial peptides.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rarely, type A reactions are seen with reused dialyzers. No association was found with the disinfectant, the reprocessing method (manual or automated), or type of dialysate (bicarbonate or acetate). Multivariate analysis showed an increased risk with the practice of washing the hemodialyzer blood compartment with either bleach or hydrogen peroxide [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Heparin and acetate can precipitate type A reactions, potentially causing severe bronchospasm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Formaldehyde [<a href="#rid20">20</a>] and natural rubber latex [<a href="#rid21">21</a>] have also been linked to anaphylactoid reactions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A type A reaction was reported in a patient with acute kidney injury requiring dialysis with a NxStage machine using a PUREMA polyethersulfone filter sterilized with gamma radiation [<a href="#rid22">22</a>]. The patient was rechallenged the following day with the same membrane and again experienced a reaction. Transitioning to another synthetic membrane (Prismaflex) was well tolerated, without recurrence.</p><p></p><p class="bulletIndent1">This case illustrates the importance of having a high index of suspicion in identifying these potentially life-threatening reactions, even if membranes not sterilized with ethylene oxide are used.</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Treatment and prevention</span><span class="headingEndMark"> — </span>The dialysis treatment is immediately stopped <strong>without returning the blood to the patient</strong>. The patient is then treated, depending upon the severity of the symptoms, with antihistamines, steroids, <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>, bronchodilators, and/or pressors.</p><p>Type A reactions can usually be prevented by proper rinsing of the dialyzer, adequate sterilization techniques for the dialysis machine, reuse of the dialyzer, and avoiding PAN membranes in patients treated with an ACE inhibitor. Sterilization of the dialyzer with gamma irradiation or steam and pretreatment with antihistamines and/or steroids may be necessary during the first use in patients with a previous history of a type A reaction.</p><p>Reuse of the dialyzer with proper sterilization techniques prevents most reactions, probably because the dialyzer membrane is coated with proteins from the patient plasma. (See  <a class="medical medical_review" href="/z/d/html/1863.html" rel="external">"Reuse of dialyzers"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">TYPE B REACTIONS</span><span class="headingEndMark"> — </span>Type B reactions are more common and fortunately less severe than type A reactions [<a href="#rid1">1</a>]. They occur in 3 to 5 percent of patients dialyzed with new cellulosic membranes. The most common symptoms are chest and back pain, dyspnea, nausea, vomiting, and hypotension. Anaphylaxis is extremely rare.</p><p>In addition to the difference in symptoms, there are two other important characteristics that distinguish these reactions from type A reactions:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms are delayed, as opposed to the usual occurrence within the first few minutes with type A reactions. Type B reactions typically begin within the <strong>first 15 to 30 minutes</strong> of the dialysis treatment but occasionally much later.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is generally an <strong>improvement</strong> in symptoms with continuation of the dialysis treatment.</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Type B reactions are believed to be mediated by <strong>complement</strong>. The free hydroxyl groups on the dialysis membrane activate the alternate pathway of complement, leading to neutrophil activation and subsequent sequestration in the pulmonary circulation [<a href="#rid23">23,24</a>] (see  <a class="medical medical_review" href="/z/d/html/1868.html" rel="external">"Biochemical mechanisms involved in blood-hemodialysis membrane interactions"</a>). These changes are frequently associated with marked and transient neutropenia, beginning as early as one minute after the start of dialysis, with the nadir in the white cell count being reached within 15 minutes. This is followed by an increased number of immature neutrophils (bands) appearing in the circulation, returning the neutrophil count to predialysis values by one hour. At this time, however, the band count may reach levels three times normal, an effect that may persist for as long as five hours  (<a class="graphic graphic_figure graphicRef51319" href="/z/d/graphic/51319.html" rel="external">figure 1</a>).</p><p>The lymphocyte count is also affected during this response. It tends to remain stable for the first 30 minutes of dialysis and then increases during the next 30 minutes to levels averaging twice the baseline value.</p><p>Animal studies have shown that the neutropenia is almost entirely explained by the sequestration of neutrophils in the pulmonary capillary bed [<a href="#rid23">23</a>]. Furthermore, the timing of activation of the complement parallels the changes in leukocyte count. C3a formation begins immediately after blood is exposed to a new cuprophane dialyzer; maximal plasma C3a levels are seen at 15 minutes and return to normal values within 10 minutes of completing dialysis  (<a class="graphic graphic_figure graphicRef61355" href="/z/d/graphic/61355.html" rel="external">figure 2</a>) [<a href="#rid25">25</a>]. Patients who exhibit the first-use syndrome consistently activate complement and raise the serum levels of C3a to a greater degree than patients who do not have this reaction [<a href="#rid24">24</a>].</p><p>Although C3a levels most accurately reflect the extent of complement activation, it is C5a that is responsible for promoting leukocyte sequestration in the lungs [<a href="#rid26">26</a>]. C5a binds to plasma membrane receptors on neutrophils, leading to activation, aggregation, and adherence [<a href="#rid27">27</a>]. This is followed by downregulation of the receptor sites with resultant cellular unresponsiveness and release of deactivated granulocytes from the pulmonary capillaries back into the circulation [<a href="#rid26">26</a>].</p><p>Complement activation is importantly determined by the type of membrane used, being progressively less as the biocompatibility of the membrane increases  (<a class="graphic graphic_figure graphicRef61355" href="/z/d/graphic/61355.html" rel="external">figure 2</a>). The types of dialysis membranes listed above can be listed in decreasing order of biocompatibility:</p><p class="bulletIndent1"><span class="glyph">●</span>Synthetic membranes (most biocompatible)</p><p class="bulletIndent1"><span class="glyph">●</span>Reused cellulose</p><p class="bulletIndent1"><span class="glyph">●</span>Cellulosynthetic (Hemophan)</p><p class="bulletIndent1"><span class="glyph">●</span>Substituted cellulose (cellulose acetate)</p><p class="bulletIndent1"><span class="glyph">●</span>Cellulose (cuprophane) (least biocompatible)</p><p></p><p>Cellulose acetate dialyzers appear to possess only approximately one-half the complement-activating property of new cuprophane dialyzers, while polyacrylonitrile (PAN) membranes induce minimal complement activation and do not lead to leukopenia [<a href="#rid26">26</a>]. Synthetic polysulfone membranes are able to activate the complement pathway, but the complement products are then absorbed, thereby blunting their effect. The degree of complement activation is also proportional to dialyzer size but not to the blood flow rate [<a href="#rid28">28,29</a>].</p><p>In contrast to the transient release of C3a and C5a, ongoing generation of the terminal complement components (C5b-9) continues throughout the dialysis session and possibly for several hours afterward [<a href="#rid30">30</a>]. The terminal complement components are able to activate mononuclear cells to release various cytokines, such as tumor necrosis factor and interleukin-1 [<a href="#rid31">31</a>]. This may contribute to other complications associated with hemodialysis such as enhanced tissue catabolism, a greater risk of infection, increased beta-2 microglobulin generation, and perhaps more rapid loss of residual kidney function. (See  <a class="medical medical_review" href="/z/d/html/1873.html" rel="external">"Clinical consequences of hemodialysis membrane biocompatibility"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Treatment and prevention</span><span class="headingEndMark"> — </span>The treatment of type B reactions is typically supportive since the symptoms characteristically resolve as dialysis is continued. The syndrome can be minimized or prevented by <strong>reuse</strong> of the dialyzer, which reduces complement activation and leukopenia by 90 percent [<a href="#rid23">23</a>] (see  <a class="medical medical_review" href="/z/d/html/1863.html" rel="external">"Reuse of dialyzers"</a>). This protective effect is thought to result from coating of the free hydroxyl groups by plasma proteins. In some cases, it may be necessary to change to a more biocompatible membrane to relieve symptoms.</p><p class="headingAnchor" id="H9"><span class="h1">OTHER REACTIONS</span><span class="headingEndMark"> — </span>Seven dialysis patients at one center developed unusual clinical features after exposure to old cellulose acetate membranes [<a href="#rid32">32</a>]. These manifestations, which appeared 7 to 24 hours after a dialysis treatment, variably included decreased vision and hearing, conjunctivitis, headache, confusion, corneal opacification, and cardiac arrest. An investigation by the Centers for Disease Control and Prevention and the Food and Drug Administration (both of the United States) concluded that the outbreak was due to exposure to cellulose acetate degradation products resulting from the use of very old (11.5 years) cellulose acetate dialyzer membranes. Thus, the stock of dialysis membranes should be properly rotated, and the manufacturers should clear the use of membranes suspected of being old. The date of manufacture is now required to be placed on all new dialyzers. </p><p class="headingAnchor" id="H10"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Acute complications are common during hemodialysis (see  <a class="medical medical_review" href="/z/d/html/1881.html" rel="external">"Acute complications during hemodialysis"</a>). Most of these intradialytic events are relatively easy to recognize and treat, and potentially fatal reactions rarely occur.</p><p>The following are specific events and their general time of onset of symptoms with respect to the initiation of the dialysis session. This is an important clue to properly diagnose and treat these events [<a href="#rid33">33</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Type A dialyzer reactions most frequently occur within the first 10 minutes; they occur less often later but still during the first hour.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The onset of type B dialyzer reactions is after 30 minutes and up to the first hour; it is uncommon after this period.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although it can happen at any time, hemolysis most often occurs during the first hour. Multiple patients may be simultaneously involved.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Air embolism most frequently occurs at dialysis initiation in patients with central venous catheters. It is uncommon otherwise but can happen at any time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dialysis-associated episodic hypotension is rare at initiation unless pericardial tamponade or valvular heart disease is present. It is more common in the later stages of treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dialysis-induced hypoxemia peaks at 30 minutes and improves after the second hour.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dialysis dysequilibrium most frequently occurs toward the end of the treatment or immediately thereafter. It may happen sooner if dialysate is hypotonic.</p><p></p><p class="headingAnchor" id="H1453243052"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of dialyzer reactions</strong> – Dialyzer reactions refer to all the abnormal sequelae resulting from the interaction between blood constituents and the hemodialysis membrane. There are two types of reactions: type A and type B. Type A is far less common but more severe than type B. (See <a class="local">'Introduction'</a> above and <a class="local">'Type A reactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type A reactions</strong> – Type A reactions are estimated to occur in approximately 4 of every 100,000 dialysis treatments. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Timing and symptoms</strong> – Type A reactions usually begin in the first few minutes of dialysis, although the onset may be delayed for up to 30 minutes. Mild symptoms include itching, burning sensation at the access site, urticaria, flushing, cough, sneezing, wheezing, abdominal cramps, diarrhea, headache, back and chest pain, nausea, vomiting, fever, and chills. More severe reactions lead to dyspnea, a sense of impending doom, and hypotension, potentially resulting in cardiac arrest and death. (See <a class="local">'Type A reactions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Etiology</strong> – Type A reactions are probably caused by leachable substances from the dialyzer (such as ethylene oxide) or by contamination with bacterial peptides. A high incidence of anaphylactoid reactions is seen when angiotensin-converting enzyme (ACE) inhibitors are used in patients treated with high-flux hemodialysis using acrylonitrile-sodium meth allyl sulfonate (AN-69) dialyzers. These membranes increase bradykinin levels. Since ACE is also a kininase, blocking the enzyme prevents inactivation of bradykinin, which increases the likelihood of an anaphylactoid reaction. (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment</strong> – The treatment of a type A reaction is stopping dialysis immediately without returning the blood to the patient. Other therapies that may be used include antihistamines, steroids, <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>, bronchodilators, and/or pressors, depending upon the severity of symptoms. (See <a class="local">'Treatment and prevention'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prevention</strong> – Type A reactions can usually be prevented by proper rinsing of the dialyzer, adequate sterilization techniques for the dialysis machine, reuse of the dialyzer, and avoiding polyacrylonitrile (PAN) membranes in patients treated with an ACE inhibitor. Sterilization of the dialyzer with gamma irradiation or steam and pretreatment with antihistamines and/or steroids may be necessary during the first use in patients with a previous history of a type A reaction. (See <a class="local">'Treatment and prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type B reactions</strong> – Type B reactions occur in 3 to 5 percent of patients dialyzed with new cellulosic membranes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Timing and symptoms</strong> – In contrast to type A reactions, type B symptoms typically do not occur until 15 to 30 minutes into the dialysis treatment, and there is generally an improvement in symptoms with continuation of the dialysis treatment. The most common symptoms are chest and back pain, dyspnea, nausea, vomiting, and hypotension. Anaphylaxis is extremely rare. (See <a class="local">'Type B reactions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pathogenesis </strong>– Type B reactions are mediated by complement. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment and prevention</strong> – The treatment of type B reactions is typically supportive since the symptoms characteristically resolve as dialysis is continued. The syndrome can be minimized or prevented by reuse of the dialyzer. (See <a class="local">'Treatment and prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis of dialyzer reactions</strong> – The differential diagnosis of type A and B reactions include other acute complications of dialysis such as hemolysis, air embolism, dialysis-associated episodic hypotension, dialysis-induced hypoxemia, and dialysis dysequilibrium. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Daugirdas JT, Ing TS. First-use reactions during hemodialysis: a definition of subtypes. Kidney Int Suppl 1988; 24:S37.</a></li><li><a class="nounderline abstract_t">Bouré T, Vanholder R. Which dialyser membrane to choose? Nephrol Dial Transplant 2004; 19:293.</a></li><li><a class="nounderline abstract_t">Lemke HD, Heidland A, Schaefer RM. Hypersensitivity reactions during haemodialysis: role of complement fragments and ethylene oxide antibodies. Nephrol Dial Transplant 1990; 5:264.</a></li><li><a class="nounderline abstract_t">Röckel A, Klinke B, Hertel J, et al. Allergy to dialysis materials. Nephrol Dial Transplant 1989; 4:646.</a></li><li><a class="nounderline abstract_t">Hertel J, Kimmel PL, Phillips TM, Bosch JP. Eosinophilia and cellular cytokine responsiveness in hemodialysis patients. J Am Soc Nephrol 1992; 3:1244.</a></li><li><a class="nounderline abstract_t">Parnes EL, Shapiro WB. Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzer. Kidney Int 1991; 40:1148.</a></li><li><a class="nounderline abstract_t">Brunet P, Jaber K, Berland Y, Baz M. Anaphylactoid reactions during hemodialysis and hemofiltration: role of associating AN69 membrane and angiotensin I-converting enzyme inhibitors. Am J Kidney Dis 1992; 19:444.</a></li><li><a class="nounderline abstract_t">Simon P, Potier J, Thebaud HE. [Risk factors for acute hypersensitivity reactions in hemodialysis]. Nephrologie 1996; 17:163.</a></li><li><a class="nounderline abstract_t">Schulman G, Hakim R, Arias R, et al. Bradykinin generation by dialysis membranes: possible role in anaphylactic reaction. J Am Soc Nephrol 1993; 3:1563.</a></li><li><a class="nounderline abstract_t">Verresen L, Fink E, Lemke HD, Vanrenterghem Y. Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes. Kidney Int 1994; 45:1497.</a></li><li><a class="nounderline abstract_t">Kuwahara T, Markert M, Wauters JP. Biocompatibility aspects of dialyzer reprocessing: a comparison of 3 re-use methods and 3 membranes. Clin Nephrol 1989; 32:139.</a></li><li><a class="nounderline abstract_t">Brophy PD, Mottes TA, Kudelka TL, et al. AN-69 membrane reactions are pH-dependent and preventable. Am J Kidney Dis 2001; 38:173.</a></li><li><a class="nounderline abstract_t">Lacour F, Maheut H. [AN 69 membrane and conversion enzyme inhibitors: prevention of anaphylactic shock by alkaline rinsing?]. Nephrologie 1992; 13:135.</a></li><li><a class="nounderline abstract_t">Thomas M, Valette P, Mausset AL, Déjardin P. High molecular weight kininogen adsorption on hemodialysis membranes: influence of pH and relationship with contact phase activation of blood plasma. influence of pre-treatment with poly(ethyleneimine). Int J Artif Organs 2000; 23:20.</a></li><li><a class="nounderline abstract_t">Maheut H, Lacour F. Using AN69 ST membrane: a dialysis centre experience. Nephrol Dial Transplant 2001; 16:1519.</a></li><li><a class="nounderline abstract_t">Pegues DA, Beck-Sague CM, Woollen SW, et al. Anaphylactoid reactions associated with reuse of hollow-fiber hemodialyzers and ACE inhibitors. Kidney Int 1992; 42:1232.</a></li><li><a class="nounderline abstract_t">John B, Anijeet HK, Ahmad R. Anaphylactic reaction during haemodialysis on AN69 membrane in a patient receiving angiotensin II receptor antagonist. Nephrol Dial Transplant 2001; 16:1955.</a></li><li><a class="nounderline abstract_t">Krieter DH, Canaud B. Anaphylactic reaction during haemodialysis on AN69 membrane in a patient receiving angiotensin II receptor antagonist. Nephrol Dial Transplant 2002; 17:943.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control (CDC). Update: acute allergic reactions associated with reprocessed hemodialyzers--United States, 1989-1990. MMWR Morb Mortal Wkly Rep 1991; 40:147, 153.</a></li><li><a class="nounderline abstract_t">Maurice F, Rivory JP, Larsson PH, et al. Anaphylactic shock caused by formaldehyde in a patient undergoing long-term hemodialysis. J Allergy Clin Immunol 1986; 77:594.</a></li><li><a class="nounderline abstract_t">Spartà G, Kemper MJ, Gerber AC, et al. Latex allergy in children with urological malformation and chronic renal failure. J Urol 2004; 171:1647.</a></li><li><a class="nounderline abstract_t">Heegard KD, Tilley MA, Stewart IJ, et al. Anaphylactoid reaction during first hemofiltration with a PUREMA polysulfone membrane. Int J Artif Organs 2013; 36:363.</a></li><li><a class="nounderline abstract_t">Craddock PR, Fehr J, Dalmasso AP, et al. Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 1977; 59:879.</a></li><li><a class="nounderline abstract_t">Hakim RM, Breillatt J, Lazarus JM, Port FK. Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med 1984; 311:878.</a></li><li><a class="nounderline abstract_t">Chenoweth DE. Complement activation during hemodialysis: clinical observations, proposed mechanisms, and theoretical implications. Artif Organs 1984; 8:281.</a></li><li><a class="nounderline abstract_t">Chenoweth DE, Cheung AK, Henderson LW. Anaphylatoxin formation during hemodialysis: effects of different dialyzer membranes. Kidney Int 1983; 24:764.</a></li><li><a class="nounderline abstract_t">Tabor B, Geissler B, Odell R, et al. Dialysis neutropenia: the role of the cytoskeleton. Kidney Int 1998; 53:783.</a></li><li><a class="nounderline abstract_t">Chenoweth DE, Henderson LW. Complement activation during hemodialysis: laboratory evaluation of hemodialyzers. Artif Organs 1987; 11:155.</a></li><li><a class="nounderline abstract_t">Bell JL, Henderson LW. Anaphylatoxin mass generated by cuprophane membranes is not influenced by blood flow rate. Kidney Int 1989; 35:240.</a></li><li><a class="nounderline abstract_t">Deppish R, Eberhard R, et al. Biocompatibility — Perspectives in 1993. Kidney Int 1994; 45:77.</a></li><li><a class="nounderline abstract_t">Dinarello CA. Cytokines: agents provocateurs in hemodialysis? Kidney Int 1992; 41:683.</a></li><li><a class="nounderline abstract_t">Hutter JC, Kuehnert MJ, Wallis RR, et al. Acute onset of decreased vision and hearing traced to hemodialysis treatment with aged dialyzers. JAMA 2000; 283:2128.</a></li><li><a class="nounderline abstract_t">Bellucci A. Shortness of breath and abdominal pain within minutes of starting hemodialysis. Semin Dial 2004; 17:417.</a></li></ol></div><div id="topicVersionRevision">Topic 1859 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2966256" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : First-use reactions during hemodialysis: a definition of subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14736948" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Which dialyser membrane to choose?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2113222" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hypersensitivity reactions during haemodialysis: role of complement fragments and ethylene oxide antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2510063" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Allergy to dialysis materials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1477320" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Eosinophilia and cellular cytokine responsiveness in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1762316" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1585932" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Anaphylactoid reactions during hemodialysis and hemofiltration: role of associating AN69 membrane and angiotensin I-converting enzyme inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9064565" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : [Risk factors for acute hypersensitivity reactions in hemodialysis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8507811" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Bradykinin generation by dialysis membranes: possible role in anaphylactic reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8072263" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2791365" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Biocompatibility aspects of dialyzer reprocessing: a comparison of 3 re-use methods and 3 membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11431198" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : AN-69 membrane reactions are pH-dependent and preventable.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1641056" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : [AN 69 membrane and conversion enzyme inhibitors: prevention of anaphylactic shock by alkaline rinsing?].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12118833" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : High molecular weight kininogen adsorption on hemodialysis membranes: influence of pH and relationship with contact phase activation of blood plasma. influence of pre-treatment with poly(ethyleneimine).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11427664" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Using AN69 ST membrane: a dialysis centre experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1453608" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Anaphylactoid reactions associated with reuse of hollow-fiber hemodialyzers and ACE inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11522894" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Anaphylactic reaction during haemodialysis on AN69 membrane in a patient receiving angiotensin II receptor antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11981096" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Anaphylactic reaction during haemodialysis on AN69 membrane in a patient receiving angiotensin II receptor antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1899901" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Update: acute allergic reactions associated with reprocessed hemodialyzers--United States, 1989-1990.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3958388" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Anaphylactic shock caused by formaldehyde in a patient undergoing long-term hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15017256" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Latex allergy in children with urological malformation and chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23420464" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Anaphylactoid reaction during first hemofiltration with a PUREMA polysulfone membrane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/856872" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6332276" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Complement activation and hypersensitivity reactions to dialysis membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6332607" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Complement activation during hemodialysis: clinical observations, proposed mechanisms, and theoretical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6609269" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Anaphylatoxin formation during hemodialysis: effects of different dialyzer membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9507227" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Dialysis neutropenia: the role of the cytoskeleton.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3496072" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Complement activation during hemodialysis: laboratory evaluation of hemodialyzers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Anaphylatoxin mass generated by cuprophane membranes is not influenced by blood flow rate</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Biocompatibility—Perspectives in 1993</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1573847" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cytokines: agents provocateurs in hemodialysis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10791505" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Acute onset of decreased vision and hearing traced to hemodialysis treatment with aged dialyzers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15461752" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Shortness of breath and abdominal pain within minutes of starting hemodialysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
